Edition:
India

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

1.35USD
17 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.35
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
61,422
52-wk High
$15.50
52-wk Low
$1.28

Latest Key Developments (Source: Significant Developments)

Diffusion Pharmaceuticals reports qtrly net income per diluted share $0.20‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals Inc qtrly net income per diluted share $0.20‍​.Diffusion Pharmaceuticals Inc - ‍remain on track to begin enrolling patients by end of 2017 for tsc glioblastoma phase 3 pivotal study​.Diffusion Pharmaceuticals Inc - ‍awaiting confirmation from Nasdaq that co demonstrated compliance with all applicable requirements for continued listing​.  Full Article

Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme.Has responded to all outstanding points raised by FDA, plans to begin trial under protocol agreed to by FDA by end of 2017​.Trial to compare survival at 2 yrs of patients receiving TSC concurrent with chemo, radiation with patients receiving SOC alone​.  Full Article

Diffusion Pharmaceuticals reports first quarter 2016 results
Tuesday, 17 May 2016 

Diffusion Pharmaceuticals Inc :Diffusion pharmaceuticals provides corporate highlights and reports first quarter 2016 results.  Full Article

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme